Fine-mapping reveals novel alternative splicing of the dopamine transporter

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 8, 2010, Pages 1434-1447

  Talkowski, Michael E ^a,b   McCann, Kathleen L ^c   Chen, Michael ^c   McClain, Lora ^a   Bamne, Mikhil ^a   Wood, Joel ^a   Chowdari, Kodavali V ^a   Watson, Annie ^a   Prasad, Konasale M ^a   Kirov, George ^d   Georgieva, Lyudmilla ^d   Toncheva, Draga ^e   Mansour, Hader ^a   Lewis, David A ^a   Owen, Michael ^d   O'Donovan, Michael ^d   Papasaikas, Panagiotis ^c   Sullivan, Patrick ^f   Ruderfer, Douglas ^g   Yao, Jeffrey K ^a,h   Leonard, Sherry ⁱ   Thomas, Pramod ^a   Miyajima, Fabio ^j   Quinn, John ^j   Lopez, A Javier ^c   Nimgaonkar, Vishwajit L ^a,b   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

Alternative splicing; Dopamine transporter; Genetic association; Schizophrenia

Indexed keywords

DOPAMINE TRANSPORTER;

ALTERNATIVE RNA SPLICING; ARTICLE; AUTOPSY; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; GENE; GENE CONSTRUCT; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; NONHUMAN; OPEN READING FRAME; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A3 GENE; SUBSTANTIA NIGRA;

ALLELES; ALTERNATIVE SPLICING; BASE SEQUENCE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXONS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MALE; OPEN READING FRAMES; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

PRIMATES;

EID: 78751706777     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31125     Document Type: Article

References (79)

1. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA. 1999. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156(10): 1580-1589.
2. Amara SG, Kuhar MJ. 1993. Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 16:73-93.
3. Armitage P. 1955. Tests for linear trends in proportions and frequencies. Biometrics 11:375-386.
4. Bamne MN, Talkowski ME, Chowdari KV, Nimgaonkar VL. 2010. Functional analysis of upstream common polymorphisms of the dopamine transporter gene. Schizophr Bull 36(5): 977-982.
5. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. 2001. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 11(6): 449-455.
6. Bannon MJ, Pruetz B, Manning-Bog AB, Whitty CJ, Michelhaugh SK, Sacchetti P, Granneman JG, Mash DC, Schmidt CJ. 2002. Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers. Proc Natl Acad Sci USA 99(9): 6382-6385.
7. Bellgrove MA, Hawi Z, Kirley A, Gill M, Robertson IH. 2005. Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: Sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype. Neuropsychologia 43(13): 1847-1857.
8. Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R, Di Giorgio A, Taurisano P, Papp A, Pinsonneault J, et al. 2009. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 132(2): 417-425.
9. Black DL. 2003. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291-336.
10. Black DL, Grabowski PJ. 2003. Alternative pre-mRNA splicing and neuronal function. Prog Mol Subcell Biol 31:187-216.
11. Brookes KJ, Mill J, Guindalini C, Curran S, Xu X, Knight J, Chen CK, Huang YS, Sethna V, Taylor E, et al. 2006. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry 63(1): 74-81.
12. Cragg SJ, Rice ME. 2004. Dancing past the DAT at a DA synapse. Trends Neurosci 27(5): 270-277.
13. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. 2005. Efficiency and power in genetic association studies. Nat Genet 37(11): 1217-1223.
14. Dean B, Hussain T. 2001. Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia. Schizophr Res 52(1-2): 107-114.
15. Fackenthal JD, Godley LA. 2008. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech 1(1): 37-42.
16. Farde L, Halldin C, Muller L, Suhara T, Karlsson P, Hall H. 1994. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse 16(2): 93-103.
17. Fuke S, Sasagawa N, Ishiura S. 2005. Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3' non-coding polymorphic region of the human dopamine transporter (DAT1) gene. J Biochem (Tokyo) 137(2): 205-216.
18. Gainetdinov RR, Sotnikova TD, Caron MG. 2002. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 23(8): 367-373.
19. Garcia-Blanco MA, Baraniak AP, Lasda EL. 2004. Alternative splicing in disease and therapy. Nat Biotechnol 22(5): 535-546.
20. Gauderman WJ. 2002. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155(5): 478-484.
21. Giros B, Caron MG. 1993. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14(2): 43-49.
22. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG. 1992. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42(3): 383-390.
23. Gorwood P, Limosin F, Batel P, Hamon M, Ades J, Boni C. 2003. The A9 allele of the dopamine transporter gene is associated with delirium tremens and alcohol-withdrawal seizure. Biol Psychiatry 53(1): 85-92.
24. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, Caillier SJ, Ban M, Goris A, Barcellos LF, et al. 2007. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39(9): 1083-1091.
25. Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, Craig I, O'Gara C, Bubb VJ, Greenwood T, et al. 2006. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci USA 103(12): 4552-4557.
26. Hall DA, Strange PG. 1999. Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3'5'-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese hamster ovary (CHO) cells. Biochem Pharmacol 58(2): 285-289.
27. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA. 2005. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25(2): 372-383.
28. Hiller M, Platzer M. 2008. Widespread and subtle: Alternative splicing at short-distance tandem sites. Trends Genet 24(5): 246-255.
29. Hirai M, Kitamura N, Hashimoto T, Nakai T, Mita T, Shirakawa O, Yamadori T, Amano T, Noguchi-Kuno SA, Tanaka C. 1988. [3H]GBR-12935 binding sites in human striatal membranes: Binding characteristics and changes in parkinsonians and schizophrenics. Jpn J Pharmacol 47(3): 237-243.
30. Hitri A, Casanova MF, Kleinman JE, Weinberger DR, Wyatt RJ. 1995. Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biol Psychiatry 37(3): 175-182.
31. Johnson MB, Kawasawa YI, Mason CE, Krsnik Z, Coppola G, Bogdanovic D, Geschwind DH, Mane SM, State MW, Sestan N. 2009. Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron 62(4): 494-509.
32. Kawarai T, Kawakami H, Yamamura Y, Nakamura S. 1997. Structure and organization of the gene encoding human dopamine transporter. Gene 195(1): 11-18.
33. Kelada SN, Costa-Mallen P, Checkoway H, Carlson CS, Weller TS, Swanson PD, Franklin GM, Longstreth WT Jr, Afsharinejad Z, Costa LG. 2005. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenet Genomics 15(9): 659-668.
34. Kirov G, Ivanov D, Williams NM, Preece A, Nikolov I, Milev R, Koleva S, Dimitrova A, Toncheva D, O'Donovan MC, et al. 2004. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol Psychiatry 55(10): 971-975.
35. Laakso A, Hietala J. 2000. PET studies of brain monoamine transporters. Curr Pharm Des 6(16): 1611-1623.
36. Laird NM, Horvath S, Xu X. 2000. Implementing a unified approach to family-based tests of association. Genet Epidemiol 19 (Suppl 1): S36-S42.
37. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R. 2000. Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [(123)I]beta-CIT. Biol Psychiatry 47(5): 371-379.
38. Lee CJ, Irizarry K. 2003. Alternative splicing in the nervous system: An emerging source of diversity and regulation. Biol Psychiatry 54(8): 771-776.
39. Lejeune F, Maquat LE. 2005. Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol 17(3): 309-315.
40. Mansour HA, Talkowski ME, Wood J, Pless L, Bamne M, Chowdari KV, Allen M, Bowden CL, Calabrese J, El-Mallakh RS, et al. 2005. Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter. Ann Med 37(8): 590-602.
41. Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, Prats A, Pons F, Bernardo M. 2005. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 181(2): 401-406.
42. Mateos JJ, Lomena F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, Prats A, Pons F, Bernardo M. 2007. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl) 191(3): 805-811.
43. Michelhaugh SK, Vaitkevicius H, Wang J, Bouhamdan M, Krieg AR, Walker JL, Mendiratta V, Bannon MJ. 2005. Dopamine neurons express multiple isoforms of the nuclear receptor nurr1 with diminished transcriptional activity. J Neurochem 95(5): 1342-1350.
44. Mick E, Kim JW, Biederman J, Wozniak J, Wilens T, Spencer T, Smoller JW, Faraone SV. 2008. Family based association study of pediatric bipolar disorder and the dopamine transporter gene (SLC6A3). Am J Med Genet Part B 147B(7): 1182-1185.
45. Miyajima F, Haddley K, Bubb VJ, Deakin JF, Pendleton N, Horan M, Ollier W, Payton A, Quinn JP. 2006. Functionality and association study of a novel variable number of tandem repeat (VNTR) polymorphism of dopamine transporter (SLC6A3) with general cognitive abilities. Am J Med Genet Part B 141B XIV World Congress on Psychiatric Genetics, abstract. (7): 769.
46. Mozley LH, Gur RC, Mozley PD, Gur RE. 2001. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158(9): 1492-1499.
47. O'Connell JR, Weeks DE. 1998. PedCheck: A program for identification of genotype incompatibilties in linakge analysis. Am J Hum Genet 63(1): 259-266.
48. O'Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G, Ball D. 2007. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 17(1): 61-67.
49. Osborne RJ, Thornton CA. 2006. RNA-dominant diseases. Hum Mol Genet 15(Spec No. 2): R162-R169.
50. Pellicano C, Buttarelli FR, Circella A, Tiple D, Giovannelli M, Benincasa D, Colosimo C, Pontieri FE. 2007. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. J Neural Transm 114(7): 935-938.
51. Prata DP, Mechelli A, Picchioni MM, Fu CH, Toulopoulou T, Bramon E, Walshe M, Murray RM, Collier DA, McGuire P. 2009. Altered effect of dopamine transporter 3'UTR VNTR genotype on prefrontal and striatal function in schizophrenia. Arch Gen Psychiatry 66(11): 1162-1172.
52. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3): 559-575.
53. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460(7256): 748-752.
54. Ranum LP, Cooper TA. 2006. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 29:259-277.
55. Richtand NM. 2006. Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 31(11): 2368-2375.
56. Rieder MJ, Livingston RJ, Stanaway IB, Nickerson DA. 2008. The environmental genome project: Reference polymorphisms for drug metabolism genes and genome-wide association studies. Drug Metab Rev 40(2): 241-261.
57. Schmauss C. 1996. Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia. J Neurosci 16(24): 7902-7909.
58. Schmitt GJ, Frodl T, Dresel S, la Fougere C, Bottlender R, Koutsouleris N, Hahn K, Moller HJ, Meisenzahl EM. 2006. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 256(2): 115-121.
59. Seeman P, Niznik HB. 1990. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 4(10): 2737-2744.
60. Sham PC, Curtis D. 1995. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59(Pt 1): 97-105.
61. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, et al. 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460(7256): 753-757.
62. Sjoholm H, Bratlid T, Sundsfjord J. 2004. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) 173(1-2): 27-31.
63. Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG. 2006. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol Disord Drug Targets 5(1): 45-56.
64. Stalder L, Muhlemann O. 2008. The meaning of nonsense. Trends Cell Biol 18(7): 315-321.
65. Steiner B, Truninger K, Sanz J, Schaller A, Gallati S. 2004. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles. Hum Mutat 24(2): 120-129.
66. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163(4): 611-622.
67. Sugnet CW, Srinivasan K, Clark TA, O'Brien G, Cline MS, Wang H, Williams A, Kulp D, Blume JE, Haussler D, et al. 2006. Unusual intron conservation near tissue-regulated exons found by splicing microarrays. PLoS Comput Biol 2(1): e4.
68. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, et al. 2008. Genomewide association for schizophrenia in the CATIE study: Results of stage 1. Mol Psychiatry 13(6): 570-584.
69. Talkowski ME, Bamne M, Mansour H, Nimgaonkar VL. 2007. Dopamine genes and schizophrenia: Case closed or evidence pending? Schizophr Bull 33(5): 1071-1081.
70. Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, Mansour H, Chowdari KV, Milanova V, Wood J, McClain L, et al. 2008. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet 17(5): 747-758.
71. Tarnok Z, Ronai Z, Gervai J, Kereszturi E, Gadoros J, Sasvari-Szekely M, Nemoda Z. 2007. Dopaminergic candidate genes in Tourette syndrome: Association between tic severity and 3' UTR polymorphism of the dopamine transporter gene. Am J Med Genet Part B 144B(7): 900-905.
72. Tobler AR, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM, Wu PP, Wang Y, Spoonde AY, Koehler RT, et al. 2005. The SNPlex genotyping system: A flexible and scalable platform for SNP genotyping. J Biomol Tech 16(4): 398-406.
73. Torres GE, Gainetdinov RR, Caron MG. 2003. Plasma membrane monoamine transporters: Structure, regulation and function. Nat Rev Neurosci 4(1): 13-25.
74. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. 1992a. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14(4): 1104-1106.
75. Vandenbergh DJ, Persico AM, Uhl GR. 1992b. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res 15(1-2): 161-166.
76. Wang J, Bannon MJ. 2005. Sp1 and Sp3 activate transcription of the human dopamine transporter gene. J Neurochem 93(2): 474-482.
77. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH. 2004. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: A dual-isotope SPECT study. Am J Psychiatry 161(8): 1496-1498.
78. Yoder KK, Hutchins GD, Morris ED, Brashear A, Wang C, Shekhar A. 2004. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 71(2-3): 371-375.
79. Zatkova A, Messiaen L, Vandenbroucke I, Wieser R, Fonatsch C, Krainer AR, Wimmer K. 2004. Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat 24(6): 491-501.